Looking beyond human papillomavirus (HPV) genotype 16 and 18: Defining HPV genotype distribution in cervical cancers in Australia prior to vaccination

No abstract is available for this paper.

• Publication year

  2017

• Venue

  International Journal of Cancer

• Publication date

  2017-10-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/ijc.30871PMID 28677147
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Age‐specific prevalence of HPV16/18 genotypes in cervical cancer: A systematic review and meta‐analysis

  2016cited by this paper
• Gardasil-9: A global survey of projected efficacy.

  2016cited by this paper
• Recent Developments in Non-HPV-related Adenocarcinomas of the Lower Female Genital Tract and Their Precursors.

  2016cited by this paper
• Laser capture microdissection as a tool to evaluate human papillomavirus genotyping and methylation as biomarkers of persistence and progression of anal lesions

  2015influential reference
• Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

  2015cited by this paper
• Human papillomavirus prevalence and type‐distribution in cervical glandular neoplasias: Results from a European multinational epidemiological study

  2015cited by this paper
• US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines.

  2015cited by this paper
• A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women.

  2015cited by this paper
• Attribution of 12 High-Risk Human Papillomavirus Genotypes to Infection and Cervical Disease

  2014cited by this paper
• Human papillomavirus (HPV) vaccination coverage in young Australian women is higher than previously estimated: independent estimates from a nationally representative mobile phone survey.

  2014cited by this paper
• Pathogenic role of the eight probably/possibly carcinogenic HPV types 26, 53, 66, 67, 68, 70, 73 and 82 in cervical cancer

  2014cited by this paper
• Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study.

  2014cited by this paper
• From the Australian Institute of Health and Welfare

  2014cited by this paper
• Prevalence of Human Papillomavirus Types in Invasive Cervical Cancers From 7 US Cancer Registries Before Vaccine Introduction

  2014cited by this paper
• How best to interpret mixed human papillomavirus genotypes in high-grade cervical intraepithelial neoplasia lesions.

  2014influential reference
• Laser capture microdissection shows HPV11 as both a causal and a coincidental infection in cervical cancer specimens with multiple HPV types

  2013cited by this paper
• Anal and perianal squamous carcinomas and high‐grade intraepithelial lesions exclusively associated with “low‐risk” HPV genotypes 6 and 11

  2013influential reference
• Estimate of the global burden of cervical adenocarcinoma and potential impact of prophylactic human papillomavirus vaccination

  2013cited by this paper
• Age-Specific Occurrence of HPV16- and HPV18-Related Cervical Cancer

  2013cited by this paper
• Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data

  2013cited by this paper
• Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study

  2013cited by this paper
• Detection of rare and possibly carcinogenic human papillomavirus genotypes as single infections in invasive cervical cancer

  2012cited by this paper
• Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease

  2012influential reference
• Biological agents. Volume 100 B. A review of human carcinogens.

  2012cited by this paper
• One virus, one lesion—individual components of CIN lesions contain a specific HPV type

  2012cited by this paper
• Fall in human papillomavirus prevalence following a national vaccination program.

  2012cited by this paper
• Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register, Australia.

  2011cited by this paper
• Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication

  2011influential reference
• Antabuse (disulfiram) as an affordable and promising anticancer drug

  2011cited by this paper
• Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study.

  2011cited by this paper
• Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data.

  2011cited by this paper
• Human papillomavirus prevalence among indigenous and non-indigenous Australian women prior to a national HPV vaccination program

  2011cited by this paper
• Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study.

  2010cited by this paper
• Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants

  2009cited by this paper
• A Systematic Review of the Prevalence and Attribution of Human Papillomavirus Types among Cervical, Vaginal, and Vulvar Precancers and Cancers in the United States

  2008cited by this paper
• How much cervical cancer in Australia is vaccine preventable? A meta-analysis.

  2008cited by this paper
• Human papillomavirus genotype prevalence in cervical biopsies from women diagnosed with cervical intraepithelial neoplasia or cervical cancer in Melbourne, Australia

  2005cited by this paper
• Cervical screening in Australia 2002–2003

  2004cited by this paper
• Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

  1999influential reference
• ‘Hit and run’ oncogenesis by human papillomavirus type 18 DNA

  1992cited by this paper
• Increased age and mortality associated with cervical carcinomas negative for human papillomavirus RNA.

  1991cited by this paper
• Association between poor prognosis in early-stage invasive cervical carcinomas and non-detection of HPV DNA.

  1990cited by this paper

• HPV42: A Common Low-Risk HPV Type Associated With Distinctive Cervicovaginal and Cutaneous Neoplasia.

  2025cites this paper
• A Review of Human Papillomavirus Prevalence and Cervical Cancer in Myanmar

  2025cites this paper
• Elimination of cervical cancer: the impact of HPV vaccination, primary HPV screening, and expanded access to cancer treatment services.

  2025cites this paper
• Towards optimal control of HPV model using safe reinforcement learning with actor-critic neural networks

  2025cites this paper
• The Prevalence of Human Papillomavirus Genotypes in Women with Precancerous Lesions and Cervical Cancer in Arequipa, Peru

  2025influential citation
• The Epithelial Immune Response to Human Papillomavirus Infection

  2025cites this paper
• High-grade squamous intraepithelial lesions and adenocarcinoma in situ with a negative HPV cervical screening test. The role of HPV-ISH testing: A retrospective review.

  2024cites this paper
• Association between Cervix Intraepithelial Neoplasia (CIN) and High-Risk Human Papillomavirus (HPV) Genotypes in Iraqi Women

  2024cites this paper
• Seegene Anyplex II Assays Detect HPV Consistently Using DNA Extracts from Different Extraction Methods.

  2024cites this paper
• Distribution of human papillomavirus among Vietnamese women with cervical cancer and unusual genetic variability of HPV16.

  2024cites this paper
• Human papillomavirus negative high grade cervical lesions and cancers: Suggested guidance for HPV testing quality assurance.

  2024cites this paper
• Predicted Cervical Cancer Prevention: Impact of National HPV Vaccination Program on Young Women in South Korea

  2024cites this paper
• Pre-Vaccination Human Papillomavirus Genotypes and HPV16 Variants among Women Aged 25 Years or Less with Cervical Cancer

  2023cites this paper
• Diversity of cervicovaginal human papillomavirus (HPV) genotypes and naturally occurring E6/E7 DNA polymorphisms of HPV-16 in Ghana

  2023cites this paper
• A Model for Empowering Rural Solutions for Cervical Cancer Prevention (He Tapu Te Whare Tangata): Protocol for a Cluster Randomized Crossover Trial

  2023cites this paper
• Electrochemical DNA Biosensors with Dual-Signal Amplification Strategy for Highly Sensitive HPV 16 Detection

  2023cites this paper
• Perceived facilitators and barriers to the uptake of the human papillomavirus (HPV) vaccine among adolescents of Arabic-speaking mothers in NSW, Australia: A qualitative study

  2023cites this paper
• Evaluation of Seegene Anyplex II Performance for Detection of Human Papillomavirus Genotypes in Formalin-Fixed, Paraffin-Embedded Cervical Cancer Specimens.

  2023cites this paper
• High Prevalence of HPV 51 in an Unvaccinated Population and Implications for HPV Vaccines

  2022cites this paper
• Distribution of human papillomavirus genotypes by severity of cervical lesions in HPV screened positive women from the ESTAMPA study in Latin America

  2022cites this paper
• The Relationships Between Social Media and Human Papillomavirus Awareness and Knowledge: Cross-sectional Study

  2022cites this paper
• Infection status and survival impact of high-risk human papillomavirus in cervical adenocarcinomas: A systematic review and meta-analysis.

  2022cites this paper
• HPV genotype prevalence in Indian women with cervical disease and estimation of the potential impact of HPV vaccines on prevention of cervical cancer.

  2022cites this paper
• Human papilloma virus genotype distribution in women with premalignant or malignant lesions of the uterine cervix

  2021cites this paper
• Study protocol: Yarning about HPV Vaccination: a qualitative study of factors influencing HPV vaccination among Aboriginal and Torres Strait Islander adolescents in Australia

  2021cites this paper
• HPV42-associated Seborrhoeic Keratosis-like Lesion of the Cervix: First Reported Case With High-grade Morphology.

  2021cites this paper
• Types and viral load of human papillomavirus, and vaginal microbiota in vaginal intraepithelial neoplasia: a cross-sectional study

  2020cites this paper
• Understanding the proportion of cervical cancers attributable to HPV

  2020cites this paper
• Burden and Prevention of HPV. Knowledge, Practices and Attitude Assessment Among Pre-Adolescents and their Parents in Italy

  2020cites this paper
• HPV Genotype Prevalence and Success of Vaccination to Prevent Cervical Cancer

  2020cites this paper
• Scientific evidence supporting recommendations on the use of the 9-valent HPV vaccine in a 2-dose vaccine schedule in Australia.

  2020cites this paper
• Assessment of attribution algorithms for resolving CIN3-related HPV genotype prevalence in mixed-genotype biopsy specimens using laser capture microdissection as the reference standard.

  2020cites this paper
• Prevalence and genotype distribution of human papillomavirus among women with cervical lesions in Shenzhen city, China

  2020cites this paper
• Could HPV Testing on Self-collected Samples Be Routinely Used in an Organized Cervical Screening Program? A Modeled Analysis

  2020cites this paper
• Human Papillomavirus Infections in Cervical Samples From HIV-Positive Women: Evaluation of the Presence of the Nonavalent HPV Genotypes and Genetic Diversity

  2020cites this paper
• Analysis of influencing factors of viral load in patients with high-risk human papillomavirus

  2020cites this paper
• Human papillomavirus genotype distribution and socio-behavioural characteristics in women with cervical pre-cancer and cancer at the start of a human papillomavirus vaccination programme: the CIN3+ plus study

  2019cites this paper
• CIN III and cervical SCC with negative oncogenic HPV PCR: A case series

  2019cites this paper
• The cost-effectiveness of controlling cervical cancer using a new 9-valent human papillomavirus vaccine among school-aged girls in Australia

  2019cites this paper
• DNA Biosensor Based on Double-Layer Discharge for the Detection of HPV Type 16

  2019influential citation
• A Lab-on-a-Chip Device Integrated DNA Extraction and Solid Phase PCR Array for the Genotyping of High-Risk HPV in Clinical Samples

  2019cites this paper
• Benefits, harms and cost-effectiveness of cancer screening in Australia: an overview of modelling estimates.

  2019cites this paper
• Recombinant human papillomavirus nonavalent vaccine in the prevention of cancers caused by human papillomavirus

  2019cites this paper
• Age-specific HPV type distribution in high-grade cervical disease in screened and unvaccinated women.

  2019cites this paper
• Routine cervical screening by primary HPV testing: early findings in the renewed National Cervical Screening Program

  2019cites this paper
• Pathways to a cancer-free future: A protocol for modelled evaluations to maximize the future impact of interventions on cervical cancer in Australia.

  2019cites this paper
• Projected future impact of HPV vaccination and primary HPV screening on cervical cancer rates from 2017–2035: Example from Australia

  2018cites this paper
• Type-specific high-risk human papillomavirus viral load as a viable triage indicator for high-grade squamous intraepithelial lesion: a nested case– control study

  2018cites this paper
• The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?

  2018influential citation
• The projected timeframe until cervical cancer elimination in Australia: a modelling study.

  2018cites this paper
• Should Cervical Cancer Screening be Performed Before the Age of 25 Years?

  2018cites this paper
• ‘Lest we forget’ as we move forward with cervical screening

  2018cites this paper
• Final analysis of a study assessing genital human papillomavirus genoprevalence in young Australian women, following eight years of a national vaccination program.

  2018cites this paper
• Efficacy, Immunogenicity, and Safety of a 9-Valent Human Papillomavirus Vaccine: Subgroup Analysis of Participants From Asian Countries

  2018cites this paper
• Human papillomavirus viral load as a useful triage tool for non-16/18 high-risk human papillomavirus positive women: A prospective screening cohort study.

  2018cites this paper
• Projected impact of HPV vaccination and primary HPV screening on cervical adenocarcinoma: Example from Australia

  2017cites this paper